Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

talimogene laherparepvec 1poly(I).poly(c12,U) 1pasireotide 1liposomal doxorubicin 1Taxes 1Tamoxifen 1Sulindac 1Palliative Care 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Metformin 1Letrozole 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunohistochemistry 1Fluorescent Antibody Technique 1Flow Cytometry 1Fatty Acids, Omega-3 1Doxorubicin 1Docosahexaenoic Acids 1Cyclophosphamide 1Celecoxib 1CTLA-4 Antigen 1Biopsy 1Bexarotene 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Carcinoma In Situ × poly(I).poly(c12,U) × Clear all
NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡